QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Summary

This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 Treatment in adults with Heterozygous Familial Hypercholesterolemia on a stable lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.

Timeline

Start

2026-05

Primary completion

2028-04

Completion

2028-07

Drugs

Indications